Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (151-160 of 324) with videos related to

Pageof 33
Sort By:
AIDS Research and Human Retroviruses|May 19, 2006
Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progressionIsaac Choge, Tonie Cilliers, Polly Walker, et al.
JAMA|September 9, 2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trialAshraf Coovadia, Elaine J Abrams, Renate Stehlau, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South AfricaGillian M Hunt, E Kainne Dokubo, Simbarashe Takuva, et al.
Virology|July 17, 2007
Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodiesCecilia Rademeyer, Penny L Moore, Natasha Taylor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South AfricaChristopher J Hoffmann, Salome Charalambous, John Sim, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Ejection Fraction Improvement Following Contemporary High-Risk Percutaneous Coronary Intervention: RESTORE EF Study ResultsJason Wollmuth, Mitul P Patel, Thom Dahle, et al.
AIDS (London, England)|March 4, 2006
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypesSoo-Yon Rhee, Rami Kantor, David A Katzenstein, et al.
The Journal of Antimicrobial Chemotherapy|October 6, 2017
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South AfricaGillian M Hunt, E Kainne Dokubo, Simbarashe Takuva, et al.
Journal of Virology|February 15, 2019
Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting VirusMichiel T van Diepen, Rosamund Chapman, Nicola Douglass, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2014
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trialNigel J Garrett, Lise Werner, Nivashnee Naicker, et al.
Pageof 33

Showing results (151-160 of 324) with videos related to

Sort By:
Pageof 33
AIDS Research and Human Retroviruses|May 19, 2006
Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progressionIsaac Choge, Tonie Cilliers, Polly Walker, et al.
JAMA|September 9, 2010
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trialAshraf Coovadia, Elaine J Abrams, Renate Stehlau, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South AfricaGillian M Hunt, E Kainne Dokubo, Simbarashe Takuva, et al.
Virology|July 17, 2007
Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodiesCecilia Rademeyer, Penny L Moore, Natasha Taylor, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2009
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South AfricaChristopher J Hoffmann, Salome Charalambous, John Sim, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Ejection Fraction Improvement Following Contemporary High-Risk Percutaneous Coronary Intervention: RESTORE EF Study ResultsJason Wollmuth, Mitul P Patel, Thom Dahle, et al.
AIDS (London, England)|March 4, 2006
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypesSoo-Yon Rhee, Rami Kantor, David A Katzenstein, et al.
The Journal of Antimicrobial Chemotherapy|October 6, 2017
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South AfricaGillian M Hunt, E Kainne Dokubo, Simbarashe Takuva, et al.
Journal of Virology|February 15, 2019
Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting VirusMichiel T van Diepen, Rosamund Chapman, Nicola Douglass, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2014
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trialNigel J Garrett, Lise Werner, Nivashnee Naicker, et al.
Pageof 33